Accéder au contenu
Merck

Mitophagy mediates metabolic reprogramming of induced pluripotent stem cells undergoing endothelial differentiation.

The Journal of biological chemistry (2021-11-18)
Sarah Krantz, Young-Mee Kim, Shubhi Srivastava, Joseph W Leasure, Peter T Toth, Glenn Marsboom, Jalees Rehman
RÉSUMÉ

Pluripotent stem cells are known to shift their mitochondrial metabolism upon differentiation, but the mechanisms underlying such metabolic rewiring are not fully understood. We hypothesized that during differentiation of human induced pluripotent stem cells (hiPSCs), mitochondria undergo mitophagy and are then replenished by the biogenesis of new mitochondria adapted to the metabolic needs of the differentiated cell. To evaluate mitophagy during iPSC differentiation, we performed live cell imaging of mitochondria and lysosomes in hiPSCs differentiating into vascular endothelial cells using confocal microscopy. We observed a burst of mitophagy during the initial phases of hiPSC differentiation into the endothelial lineage, followed by subsequent mitochondrial biogenesis as assessed by the mitochondrial biogenesis biosensor MitoTimer. Furthermore, hiPSCs undergoing differentiation showed greater mitochondrial oxidation of fatty acids and an increase in ATP levels as assessed by an ATP biosensor. We also found that during mitophagy, the mitochondrial phosphatase PGAM5 is cleaved in hiPSC-derived endothelial progenitor cells and in turn activates β-catenin-mediated transcription of the transcriptional coactivator PGC-1α, which upregulates mitochondrial biogenesis. These data suggest that mitophagy itself initiates the increase in mitochondrial biogenesis and oxidative metabolism through transcriptional changes during endothelial cell differentiation. In summary, these findings reveal a mitophagy-mediated mechanism for metabolic rewiring and maturation of differentiating cells via the β-catenin signaling pathway. We propose that such mitochondrial-nuclear cross talk during hiPSC differentiation could be leveraged to enhance the metabolic maturation of differentiated cells.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Antimycine A from Streptomyces sp.
Sigma-Aldrich
CHIR99021, ≥98% (HPLC)
Sigma-Aldrich
Oligomycine A, ≥99% (HPLC)
Sigma-Aldrich
Cyanure de 4-(trifluorométhoxy)phénylhydrazone carbonyle, ≥98% (TLC), powder
Sigma-Aldrich
Roténone, ≥95%
Millipore
Cocktail d'inhibiteurs de protéases III, sans EDTA, Protease inhibitor cocktail III, EDTA-free for inhibiting aspartic, cysteine, and serine proteases as well as aminopeptidases in mammalian cells and tissues.
Sigma-Aldrich
L-Carnitine hydrochloride, synthetic, ≥98%
Sigma-Aldrich
Sodium palmitate, ≥98.5%
Sigma-Aldrich
IWR-1, ≥98% (HPLC)
Sigma-Aldrich
TGF-β RI Kinase Inhibitor VI, SB431542, InSolution, ≥97%
Millipore
Set de cocktail d′inhibiteurs de phosphatases II, A cocktail of five phosphatase inhibitors for the inhibition of acid and alkaline phosphatases as well as protein tyrosine phosphatases (PTPs). Suitable for use with cell lysates and tissue extracts.